Education
About Us
Working with TipRanks
Follow Us
Bioxytran Inc (BIXT)
OTHER OTC:BIXT
Total Valuation
Bioxytran has a market cap or net worth of $8.53M. The enterprise value is ―.
Market Cap$8.53M
Enterprise Value―
Share Statistics
Bioxytran has 98,898,384 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding98,898,384
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Bioxytran’s return on equity (ROE) is 1.32 and return on invested capital (ROIC) is 318.55%.
Return on Equity (ROE)1.32
Return on Assets (ROA)-17.06
Return on Invested Capital (ROIC)318.55%
Return on Capital Employed (ROCE)1.24
Revenue Per Employee0.00
Profits Per Employee-793.34K
Employee Count3
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Bioxytran is ―. Bioxytran’s PEG ratio is 0.11.
PE Ratio―
PS Ratio0.00
PB Ratio-6.95
Price to Fair Value-6.95
Price to FCF-148.45
Price to Operating Cash Flow-29.52
PEG Ratio0.11
Income Statement
In the last 12 months, Bioxytran had revenue of 0.00 and earned -2.37M in profits. Earnings per share was -0.02.
Revenue0.00
Gross Profit-7.95K
Operating Income-2.22M
Pretax Income-2.38M
Net Income-2.37M
EBITDA-2.22M
Earnings Per Share (EPS)-0.02
Cash Flow
In the last 12 months, operating cash flow was -247.17K and capital expenditures -10.33K, giving a free cash flow of -257.50K billion.
Operating Cash Flow-247.17K
Free Cash Flow-257.50K
Free Cash Flow per Share>-0.01
Dividends & Yields
Bioxytran pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-1.59
52-Week Price Change-11.11%
50-Day Moving Average0.07
200-Day Moving Average0.10
Relative Strength Index (RSI)54.73
Average Volume (3m)219.43K
Important Dates
Bioxytran upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Bioxytran as a current ratio of <0.01, with Debt / Equity ratio of -29.44%
Current Ratio<0.01
Quick Ratio<0.01
Debt to Market Cap0.09
Net Debt to EBITDA-0.49
Interest Coverage Ratio-2.89
Taxes
In the past 12 months, Bioxytran has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Bioxytran EV to EBITDA ratio is -6.09, with an EV/FCF ratio of -161.43.
EV to Sales0.00
EV to EBITDA-6.09
EV to Free Cash Flow-161.43
EV to Operating Cash Flow-243.09
Balance Sheet
Bioxytran has $14.50K in cash and marketable securities with $855.00K in debt, giving a net cash position of -$840.50K billion.
Cash & Marketable Securities$14.50K
Total Debt$855.00K
Net Cash-$840.50K
Net Cash Per Share>-$0.01
Tangible Book Value Per Share-$0.01
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Bioxytran is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―